TriNetX real-world data enable study of COVID-19 vaccine patients

By The Science Advisory Board staff writers

February 18, 2021 -- Global health research network TriNetX announced that COVID-19 vaccination data are available in its TriNetX platform and real-world dataset for clinical and observational research.

The data come from more than 100,000 patients who have received either the Pfizer-BioNTech or Moderna COVID-19 vaccines.

The COVID-19 vaccination data are now harmonized with years of longitudinal patient history on the TriNetX network, according to Brecht Claerhout, chief data officer at TriNetX.

"This is a significant milestone for the research community to better understand treatments and outcomes including adverse events such as reinfection," said Claerhout. "It is crucially important for researchers to follow these patients on a go-forward basis, and that is an area where TriNetX can help."

TriNetX is also contributing data to the National COVID Cohort Collaborative (N3C), an initiative led by the U.S. National Institutes of Health that seeks to develop analytics that clinical centers, researchers, and physicians can use to cope with COVID-19, according to the firm.

The company will host a webinar on February 24 to demonstrate how its COVID-19 vaccination data can be used.

TriNetX updates platform to support COVID-19 research
Global health research network TriNetX said that it has updated its real-world data platform to incorporate specific terminology for COVID-19 test results.

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter